Related references
Note: Only part of the references are listed.2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options
Edoardo Gronda et al.
HEART FAILURE REVIEWS (2020)
Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Milton Packer
AMERICAN JOURNAL OF NEPHROLOGY (2020)
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure
Milton Packer
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Heart Failure With Reduced Ejection Fraction A Review
Sean P. Murphy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Faiez Zannad et al.
LANCET (2020)
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors A State-of-the-Art Review
Gary D. Lopaschuk et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)
Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia/reperfusion injury
Zhao Li et al.
CARDIOVASCULAR RESEARCH (2019)
Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality
Mehmet Kanbay et al.
DIABETES OBESITY & METABOLISM (2019)
Unresolved issues in left ventricular postischemic remodeling and progression to heart failure
Edoardo Gronda et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2019)
An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
Ernest Adeghate et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Peripheral artery disease: the new frontiers of imaging techniques to evaluate the evolution of regenerative medicine
Marco Miceli et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2019)
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Merlin C. Thomas et al.
DIABETOLOGIA (2018)
Development of SGLT1 and SGLT2 inhibitors
Timo Rieg et al.
DIABETOLOGIA (2018)
SGLT1 inhibition: Pros and cons
Vasilis Tsimihodimos et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Novel hemodynamic structures in the human glomerulus
Christopher R. Neal et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
Urinary adenosine excretion in type 1 diabetes
Harindra Rajasekeran et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2017)
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes
Hussein Al-Jobori et al.
DIABETES (2017)
Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis
K. Melissa Hallow et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2017)
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade
Michael A. Weber et al.
BLOOD PRESSURE (2016)
No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?
Bruce A. Perkins et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
Michael A. Weber et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Renal function impairment predicts mortality in patients with chronic heart failure treated with resynchronization therapy
Edoardo Gronda et al.
CARDIOLOGY JOURNAL (2015)
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
Matthew A. Cavender et al.
CIRCULATION (2015)
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study
S. Sha et al.
DIABETES OBESITY & METABOLISM (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Anoop Dinesh Shah et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
Julio Rosenstock et al.
DIABETES CARE (2015)
Localizations of Na+-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
Ivana Vrhovac et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2015)
Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats
Naoki Kojima et al.
PHYSIOLOGICAL REPORTS (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure
Irving H. Zucker et al.
CLINICAL SCIENCE (2014)
Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models
David R. Powell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
Muhammad A. Abdul-Ghani et al.
DIABETES (2013)
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo et al.
DIABETES CARE (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
Scott C. Thomson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2012)
Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen (Jim) Liu et al.
DIABETES (2012)
Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes
Piero Ruggenenti et al.
DIABETES CARE (2012)
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
S. Sha et al.
DIABETES OBESITY & METABOLISM (2011)
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
Frank A. Holtkamp et al.
KIDNEY INTERNATIONAL (2011)
Glycaemic control and incidence of heart failure in 20 985 patients with type 1 diabetes: an observational study
Marcus Lind et al.
LANCET (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework
Claudio Napoli et al.
FUTURE CARDIOLOGY (2011)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
L. Zhang et al.
DIABETES OBESITY & METABOLISM (2010)
Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials
R. A. DeFronzo et al.
DIABETIC MEDICINE (2010)
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
J. E. Gerich
DIABETIC MEDICINE (2010)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis
G. M. Magee et al.
DIABETOLOGIA (2009)
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure
Michael R. MacDonald et al.
EUROPEAN HEART JOURNAL (2008)
Adenosine and kidney function: Potential implications in patients with heart failure
Volker Vallon et al.
EUROPEAN JOURNAL OF HEART FAILURE (2008)
Phlorizin Prevents Glomerular Hyperfiltration but not Hypertrophy in Diabetic Rats
Slava Malatiali et al.
EXPERIMENTAL DIABETES RESEARCH (2008)
Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes
Etienne B. Sochett et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Insulin resistance and risk of congestive heart failure
E Ingelsson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat
S Vestri et al.
JOURNAL OF MEMBRANE BIOLOGY (2001)
Share Paper
